CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Multicancer Early Detection (MCED) Tests — Coverage Criteria

This policy governs coverage for multicancer early detection (MCED) liquid biopsy screening tests (for example, Galleri) for asymptomatic individuals and applies to commercial and Medicare Advantage products administered by Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMulticancer Early Detection (MCED) Tests — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionVerify member benefits and refer to the Benefit Booklet/Evidence of Coverage because MCED screening tests are not covered and benefits may vary by contract.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

not coveredMCED tests for cancer screening

No FDA approvalFDA status

InsufficientEvidence

Use UnlistedCoding

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MCED tests for cancer screening

Not covered when used for cancer screening in asymptomatic individuals.

Screening indication: The use of multicancer early detection (MCED) tests (e.g., Galleri) for cancer screening of asymptomatic individuals is considered not covered/not medically necessary because the evidence is insufficient to demonstrate improvement in net health outcomes.evidence insufficient

Performance characteristics in intended-use screening populations and impact on cancer-specific mortality, overdiagnosis, and downstream outcomes are unknown.

The use of multicancer early detection (MCED) tests (e.g., Galleri) for screening asymptomatic individuals is not covered / not medically necessary. The policy determination is based on insufficient evidence that MCED screening improves net health outcomes, including lack of data showing effects on cancer-specific mortality, overdiagnosis, or clinically meaningful benefits in the intended screening population.

Published studies to date have largely enrolled patients with known cancer or selected case-control cohorts rather than asymptomatic screening populations; therefore, estimates of sensitivity, specificity, positive and negative predictive values, and downstream impacts on survival and overtreatment in a screening setting are not established.

Coverage for MCED testing may be further limited by the member’s specific contract or benefit booklet. Benefits can vary between employer groups and plans; some genetic testing services may be contractually excluded under other policies (for example, the Biomarker Testing Mandate).

Providers and billing staff should verify benefits and any applicable exclusions or authorization requirements by reviewing the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement before ordering or submitting claims.

Covered Indications

None specified; MCED tests for screening asymptomatic individuals are not covered.

Coverage may be further restricted by contract; verify member benefits.

Contractual exclusions and benefit verification: Some employer groups or plans may have contractual exclusions or customized benefit coverage that limit or exclude genetic testing services, including MCED tests; providers must refer to the member's Benefit Booklet/Evidence of Coverage/Subscriber Agreement to determine specific coverage or exclusions.

This policy does not guarantee payment; benefit verification is required.

Coding Guidance

Coding guidanceCPT

Unlisted code(s)

No specific CPT codes assigned to MCED tests; use unlisted CPT code(s).

Evidence thresholds

SummaryEvidence insufficient to demonstrate improved net health outcomes; sensitivity, specificity, predictive values, and impact on cancer-specific mortality are not established for screening populations.

Study populationsPublished clinical validity studies primarily included patients with established cancer and healthy controls, not the intended asymptomatic screening population.

Performance characteristicsEstimates of sensitivity, specificity, false-positives, false-negatives, and predictive values in the intended-use screening population are not available.

Clinical outcomes unknownChanges in overall or cancer-specific mortality, quality of life, functional outcomes, overdiagnosis, and overtreatment have not been demonstrated.

ImplicationInsufficient evidence that MCED screening improves net health outcomes; therefore policy considers MCED screening not medically necessary / not covered.

Provider Actions & Billing Notes

Prior Authorization

No prior authorization is applicable per this policy. However, benefits and prior authorization requirements may vary by contract; providers should verify eligibility and any prior authorization requirements with the member's plan.

Benefits may vary by group/contract — check the member's Benefit Booklet/Evidence of Coverage/Subscriber Agreement

Denial Risk

Denial Risk for MCED Screening

Claims for MCED tests submitted for cancer screening indications are at risk of denial because the tests are considered not covered / not medically necessary for screening.

MCED tests (e.g., Galleri) for asymptomatic population screening — not covered / not medically necessary

Documentation Required

Benefit Verification Required

Providers must verify member benefits and coverage details before ordering MCED testing. Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine plan-specific coverage, exclusions, and any prior authorization requirements.

Confirm whether the member's plan includes expanded biomarker/genetic testing coverage or specific exclusions
Contact the provider call center for member-specific benefit information

Note

Provider Actions — Counseling & Ordering

The policy does not specify pre- or post-test genetic counseling requirements for MCED tests and does not specify who may order MCED tests. Providers should follow applicable state laws, clinical guidelines, and the member's plan rules when determining counseling needs and ordering privileges.

No policy-specified requirement for genetic counseling
No policy-specified provider ordering restrictions — verify with plan or participation agreement

Definitions

Multicancer early detection (MCED) test

DefinitionA multicancer early detection (MCED) test is a minimally invasive liquid biopsy intended to detect multiple cancer types (for example, cell-free DNA methylation–based assays such as Galleri).

Use caseDesigned for screening asymptomatic populations to detect preclinical cancers or precursor lesions.

Regulatory statusNo MCED tests have been approved or cleared by the FDA as of the policy; some (e.g., Galleri) have received FDA breakthrough device designation and are offered as laboratory-developed tests under CLIA.

Evidence limitationsPublished studies have mainly included patients with known cancer rather than intended screening populations, limiting applicability of performance estimates.

Laboratory-developed test (LDT)

DefinitionLaboratory-developed test (LDT): a test developed and validated in-house by a clinical laboratory and offered under the Clinical Laboratory Improvement Amendments (CLIA) for high-complexity testing.

Regulatory frameworkLDTs are marketed as laboratory services and must meet CLIA general regulatory standards; the FDA has historically not required premarket review of some LDTs (e.g., Galleri to date).

AvailabilitySome MCED tests are available as LDTs and are offered under CLIA high-complexity testing requirements.

Background

Early detection of cancer can improve prognosis in some settings, which motivates development of screening strategies. Multicancer early detection (MCED) tests are minimally invasive cell-free DNA (cfDNA)–based assays (for example, methylation-based tests such as Galleri) intended to detect signals from multiple cancer types from a blood sample.

However, the published evidence for MCED testing in screening settings is limited. Most clinical validity studies have included patients with established cancers and healthy controls rather than the intended asymptomatic screening population, so performance characteristics (sensitivity, specificity, predictive values), the optimal target populations, screening frequency, and the impact on cancer-specific mortality, overdiagnosis, and downstream harms are not well defined. No MCED test addressed in this policy has been shown to improve net health outcomes for population screening.

Eligibility Requirements

This policy does not specify any top-level eligibility criteria or covered indications for MCED testing; there are no coverage provisions supporting MCED use for asymptomatic population screening.

There are no duplicate or related eligibility provisions defined in this policy. The policy provides no authorization or clinical eligibility pathways that would permit MCED testing for routine screening of asymptomatic individuals.